Optilite® Freelite® Assays

Clinical laboratories managing serum-free light chain (sFLC) testing often face pressure to reduce turnaround times, minimize manual interventions, and control reagent use. This case study explores the impact of moving Freelite® assays from the Roche cobas™ 8000 to the Optilite® analyzer, assessing 306 routine specimens and 48 elevated FLC samples. The results demonstrate faster workflows, meaningful reagent savings, and the complete removal of manual dilutions to streamline sFLC testing while reducing error‑prone steps.

Quantifying serum proteins is essential for diagnosing and monitoring a wide range of conditions, yet laboratories often struggle with poor analytical performance, high dilution burdens, and intensive maintenance on high‑throughput chemistry lines.

Explore how moving special protein testing to the Optilite® standalone analyzer can improve workflow efficiency and reduce manual intervention, providing faster analytical times, even for assays requiring dilution.

In this case study, Binding Site presents the advantages of integrating Clinical Decision Support (CDS) tools into the diagnostic investigation process for multiple myeloma, drawn from the successful implementation of guideline-based sFLC suggestive alerts at Massachusetts General Hospital, US.

In this case study, Binding Site presents the advantages of integrating testing panels into the diagnostic investigation process for multiple myeloma (MM), drawn from the experiences of Hospital Universitario Donostia, Spain.

By investigating the implementation of a testing panel comprising serum protein electrophoresis (SPE) and serum free light chain (sFLC) tests for MM, Hospital Universitario Donostia observed significant benefits from adopting the panel.

In this case study, Binding Site presents the advantages of integrating Clinical Decision Support (CDS) tools into the diagnostic investigation process for multiple myeloma, drawn from the experiences of Hampshire Hospitals, NHS Foundation Trust, Basingstoke, UK.

Benefits observed included a reduction in inappropriate referrals, improved urgent patient review times, and a reduction in associated costs.

In this case study, Binding Site presents the advantages of integrating testing panels into the diagnostic investigation process for multiple myeloma, drawn from the experiences of St. Elizabeth Healthcare, Edgewood, KY, US.

By implementing a testing panel for myeloma that combines serum free light tests (sFLC) and serum protein electrophoresis (SPE) tests into a single order, St. Elizabeth Healthcare observed significant benefits.

Monday, November 17, at 16:00 GMT | 17:00 CET | 11:00 EST | 8:00 PST

Multiple myeloma (MM) is among the cancers having the longest delay from first symptoms to diagnosis. Patients often initially present to their primary care providers (PCPs) and may visit multiple times before being referred to a specialist. Laboratory testing is pivotal in the diagnostic workup, especially in primary care settings where initial investigations often occur.

The College of American Pathologists (CAP) has published guidelines for the laboratory detection and initial diagnosis of monoclonal gammopathies in 2022. Timely diagnosis has been proven to result in fewer complications and improved patient outcomes. Despite significant advancement in the understanding of MM biology and clear guidelines around diagnostic testing, the status of US PCPs’ understanding of MM diagnostic testing practices remain understudied.

This webinar will share the key findings of a national survey of US PCPs, the first of its kind, assessing the awareness of recommended MM diagnostic workup as well as the current approach to MM diagnosis among US PCPs. We will identify opportunities to improve laboratory test ordering practices and enhance patient care.

Join us to advance your understanding and approach to MM diagnosis.

Key learning objectives:

• Understand the importance of timely and guideline-compliant testing for MM and related plasma cell disorders.
• Assess the current knowledge and practices of US primary care providers (PCPs) regarding MM diagnostic testing and diagnosis.
• Explore how US PCPs are utilizing laboratory services and identify additional support needed to improve testing and patient care.
• Learn practical steps and frameworks to enhance guideline-compliant MM laboratory test ordering practices.

Who should attend?

Laboratory professionals, laboratory directors/decision makers, medical directors, primary care providers, and hematologists/oncologists.

Accreditation statement

SelectScience® is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.

Guest editorial by Dale Powner, Country Manager for the UK, Ireland and Nordics at Binding Site, part of Thermo Fisher Scientific